Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs has launched an extensive range of CD47 CAR-related items including CAR vectors, CAR viral particles, and CAR cell products, to facilitate the advancement of CD47-targeted antibody-based CAR-T therapy. Feel free to explore and discover the specific product that piques your interest.
Cluster of Differentiation 47 (CD47) is a glycoprotein expressed in all cells in the body and, in particular, overexpressed in cancer cells and cancer stem cells. In the immune system, the role of CD47 is to prevent macrophages from engulfing cells by sending a signal of "Do not eat me", which is accomplished by interacting with signal regulatory protein α (SIRPα). CD47 has been associated with the invasion of tumors and metastasis in cancer.
Fig.1 Variable expression of CD47 in different cell lines.1
We offer a full range of CD47 protein products:
-Unconjugated CD47
-Biotinylated CD47
-Fluorescent-labeled CD47
-Custom cells with CD47 overexpression
Fig.2 Generation of lentivirus through the HEK 293FT cell.2
Fig.3 CAR-T cells on confocal microscope.2
CD47 CAR-T Cytokine Release Test
The capability to release cytokines (such as IL-2 and IFNg) of CD47 CAR-T cells when interacting with cancer cells can be assessed by ELISA. We provide custom cytokine release tests according to the customer's requirements.
Fig.4 Capability of CAR-T Cell to Release IL-2.2
Fig.5 Capability of CAR-T Cell to Release IFNg.2
CD47 CAR-T In Vitro Cytotoxicity Assay
Luciferase assay and lactate dehydrogenase (LDH) assay are extremely useful as a detection method to evaluate cell proliferation of CD47 CAR-T cells.
CD47 CAR-T Cell Proliferation Test
We offer a full list of CAR testing services including carboxyfluorescein succinimidyl ester (CFSE)-based cell proliferation, to make sure the CAR T cells are effective once they come across the target cells.
CD47 CAR-T Cell Therapy Animal Models
A wide range of animal models, syngeneic models, humanized mice models, and patient-derived xenografted (PDX) models are available at Creative Biolabs for efficacy and toxicity evaluation.
BxPC3 pancreatic cancer cells can be used to test the efficacy of CD47-CAR-T cells in vivo.
Fig.6 CD47-CAR-T cells can effectively kill BxPC3 cancer cell lines.1
Toxicity Evaluation of CD47 CAR-T
Research has indicated that CD47 CAR-T cells possess remarkable cytotoxicity towards cancer cells that express CD47, including SKOV-3, A1847, pancreatic, and BxPC3 cancer cell lines. In contrast, their cytotoxicity is comparatively lower against the Hela-CD19 cancer cell line, which exhibits lower levels of CD47 expression.
Fig.7 High cytotoxicity of CD47 CAR-T cells against CD47-positive cancer cells.1
Please don't hesitate to reach out to us for further information and offerings regarding CD47 CAR-T services and products.
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-YF249 | Anti-CD47 (CBL-YF065) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CBL-YF065 | Humanized | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-YF250 | Anti-CD47 (CBL-YF065) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBL-YF065 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP174 | Anti-CD47 (6BH12) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 6BH12 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP175 | Anti-CD47 (6BH12) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 6BH12 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP5941 | Anti-CD47 (huB6H12) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | huB6H12 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP5974 | Anti-CD47 (OX101) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | OX101 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP5975 | Anti-CD47 (MEM-122) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | MEM-122 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP5976 | Anti-CD47 (MEM-122) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | MEM-122 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP5977 | Anti-CD47 (PF3.1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PF3.1 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP5978 | Anti-CD47 (PF3.1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | PF3.1 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP5979 | Anti-CD47 (C5/D5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C5/D5 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0622-ZP3326 | Anti-CD47 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0622-ZP3498 | Anti-CD47 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0722-ZP4314 | Anti-CD47 (B5712) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | B5712 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-ZP4315 | Anti-CD47 (B5713) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | B5713 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-ZP4316 | Anti-CD47 (B5714) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | B5714 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-ZP4317 | Anti-CD47 (B5715) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | B5715 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-ZP4318 | Anti-CD47 (B5716) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | B5716 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-ZP4319 | Anti-CD47 (hum01) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | hum01 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0722-ZP4320 | Anti-CD47 (hum02) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | hum02 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
